Investigators from University of Rochester Report New Data on CDC and FDA (New Design Strategies for Ultra-specific Crispr-cas13a-based Rna Detection With Single-nucleotide Mismatch Sensitivity).

A recent study conducted by researchers at the University of Rochester in New York has explored new design strategies for ultra-specific RNA detection using the CRISPR-Cas13a system. The researchers aimed to develop nucleic acid-based detection technologies that are sensitive, fast, inexpensive, and suitable for point-of-care use. They found that certain positions in the RNA-detection system were particularly sensitive to mismatches and established the effect of RNA concentration on mismatch tolerance. By modifying the system, they were able to achieve superior discrimination of SARS-CoV-2 strains compared to the wild-type system. This research provides new design criteria and variants for future Cas13-based RNA detection applications. [Extracted from the article]

Copyright of Medical Letter on the CDC & FDA is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)